Merck’s P-III Trial Assessing Keytruda Met its Secondary Endpoint in Renal Cell Carcinoma (RCC) Patients
Shots:
- The P-III (KEYNOTE-564) clinical trial evaluates the safety and efficacy of Keytruda (200mg, IV at 3wks cycle for 17cycles) vs PBO as adjuvant treatment for patients (n=994) with RCC at intermediate-high/high risk of recurrence following nephrectomy with/out resection of metastatic lesions in the ratio 1:1. The 1EP of the study includes DFS & 2EPs includes OS & safety
- The company reported that the study depicted a statistically significant & clinically meaningful improvement in OS vs PBO whereas the safety data were consistent with previous studies
- Earlier, the (KEYNOTE-564) study met its 1EP of DFS with a 32% reduction in risk of disease recurrence or death vs PBO
Ref: Merck | Image: Merck
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
